JAZZ FY 2024 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4.1B+6.1% YoY

Gross Profit

$3.6B89.0% margin

Operating Income

$717M17.6% margin

Net Income

$560M13.8% margin

EPS (Diluted)

$8.65

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.3B

Stock-Based Comp.

$248M

Balance Sheet

Total Assets

$12.0B

Total Liabilities

$7.9B

Stockholders' Equity

$4.1B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.1B	$3.8B	+6.1%
Gross Profit	$3.6B	$3.4B	+6.6%
Operating Income	$717M	$579M	+23.9%
Net Income	$560M	$415M	+35.0%